JP2021501788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501788A5 JP2021501788A5 JP2020524826A JP2020524826A JP2021501788A5 JP 2021501788 A5 JP2021501788 A5 JP 2021501788A5 JP 2020524826 A JP2020524826 A JP 2020524826A JP 2020524826 A JP2020524826 A JP 2020524826A JP 2021501788 A5 JP2021501788 A5 JP 2021501788A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- formula
- halo
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AMBAWAHKHZZAAY-UHFFFAOYSA-N CCC(C)c1c(C)cccc1 Chemical compound CCC(C)c1c(C)cccc1 AMBAWAHKHZZAAY-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580740P | 2017-11-02 | 2017-11-02 | |
| US62/580,740 | 2017-11-02 | ||
| US201862643074P | 2018-03-14 | 2018-03-14 | |
| US62/643,074 | 2018-03-14 | ||
| PCT/US2018/058969 WO2019090085A1 (en) | 2017-11-02 | 2018-11-02 | Modulators of the integrated stress pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501788A JP2021501788A (ja) | 2021-01-21 |
| JP2021501788A5 true JP2021501788A5 (enExample) | 2021-12-09 |
Family
ID=64572459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524826A Pending JP2021501788A (ja) | 2017-11-02 | 2018-11-02 | 統合的ストレス経路の調節剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210169892A1 (enExample) |
| EP (1) | EP3704090A1 (enExample) |
| JP (1) | JP2021501788A (enExample) |
| KR (1) | KR20200096226A (enExample) |
| CN (1) | CN112218850A (enExample) |
| AU (2) | AU2018360853B2 (enExample) |
| BR (1) | BR112020008830A2 (enExample) |
| CA (1) | CA3080968A1 (enExample) |
| IL (1) | IL274405A (enExample) |
| MX (1) | MX2020004558A (enExample) |
| SG (1) | SG11202004018VA (enExample) |
| TW (1) | TWI813596B (enExample) |
| UY (1) | UY37958A (enExample) |
| WO (1) | WO2019090085A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| CN111094233B (zh) | 2017-08-09 | 2024-03-15 | 戴纳立制药公司 | 化合物、组合物及方法 |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| RU2020122711A (ru) | 2017-12-13 | 2022-01-17 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы пути интегрированной реакции на стресс |
| SG11202011014VA (en) | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| AU2020261234A1 (en) | 2019-04-23 | 2021-11-11 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EA202192900A1 (ru) | 2019-04-23 | 2022-03-18 | Эвотек Интернешнл Гмбх | Модуляторы пути интегрированной реакции на стресс |
| AU2020266592A1 (en) * | 2019-04-30 | 2021-12-02 | Abbvie Inc. | Substituted cyclolakyls as modulators of the integrated stress pathway |
| PH12021552759A1 (en) * | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| KR20220133252A (ko) | 2020-01-28 | 2022-10-04 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절자 |
| JP2023517944A (ja) | 2020-03-11 | 2023-04-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| AU2021366303A1 (en) | 2020-10-22 | 2023-06-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| EP4237413A1 (en) * | 2020-10-30 | 2023-09-06 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| AU2014233520B2 (en) * | 2013-03-15 | 2019-02-21 | The Regents Of The University Of California | Modulators of the eIF2alpha pathway |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW202506629A (zh) * | 2016-05-05 | 2025-02-16 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
-
2018
- 2018-11-01 UY UY0001037958A patent/UY37958A/es not_active Application Discontinuation
- 2018-11-02 US US16/761,354 patent/US20210169892A1/en not_active Abandoned
- 2018-11-02 JP JP2020524826A patent/JP2021501788A/ja active Pending
- 2018-11-02 BR BR112020008830-7A patent/BR112020008830A2/pt not_active Application Discontinuation
- 2018-11-02 CA CA3080968A patent/CA3080968A1/en active Pending
- 2018-11-02 MX MX2020004558A patent/MX2020004558A/es unknown
- 2018-11-02 SG SG11202004018VA patent/SG11202004018VA/en unknown
- 2018-11-02 CN CN201880085190.8A patent/CN112218850A/zh active Pending
- 2018-11-02 KR KR1020207015793A patent/KR20200096226A/ko not_active Ceased
- 2018-11-02 EP EP18812425.9A patent/EP3704090A1/en active Pending
- 2018-11-02 AU AU2018360853A patent/AU2018360853B2/en not_active Expired - Fee Related
- 2018-11-02 WO PCT/US2018/058969 patent/WO2019090085A1/en not_active Ceased
- 2018-11-02 TW TW107138980A patent/TWI813596B/zh active
-
2020
- 2020-05-03 IL IL274405A patent/IL274405A/en unknown
-
2023
- 2023-06-20 AU AU2023203860A patent/AU2023203860B2/en active Active
- 2023-09-07 US US18/463,183 patent/US20240000792A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501788A5 (enExample) | ||
| JP2021501785A5 (enExample) | ||
| JP2021501780A5 (enExample) | ||
| JP2021501786A5 (enExample) | ||
| JP2021501787A5 (enExample) | ||
| JP2021501789A5 (enExample) | ||
| JP2021501781A5 (enExample) | ||
| JP2021501790A5 (enExample) | ||
| JP2021501779A5 (enExample) | ||
| RU2020117900A (ru) | Модуляторы интегрированного стресса | |
| CN101678014B (zh) | 杂环激酶调节剂 | |
| EP1369421B1 (en) | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives | |
| CN106459076B (zh) | 用于诱导软骨发生的化合物和组合物 | |
| RU2020117927A (ru) | Модуляторы интегрированного стресса | |
| CN103214484A (zh) | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 | |
| TW202322819A (zh) | 含氮的四環化合物、其製備方法及其在醫藥上的應用 | |
| JP2015501134A5 (enExample) | ||
| JP2016500119A (ja) | ブルトン型チロシンキナーゼ阻害剤 | |
| JPWO2020223536A5 (enExample) | ||
| JP2021152056A (ja) | 疾患を治療するためのｍｃｔ４阻害剤 | |
| AU2019344928A1 (en) | Pyridazinones and methods of use thereof | |
| WO2024040080A1 (en) | Kras inhibitor conjugates | |
| US10864203B2 (en) | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer | |
| EA037416B1 (ru) | Слитый белок для обезболивания и/или профилактики возникновения боли | |
| JP2022512824A (ja) | Ａｌｋ２阻害剤の結晶形 |